HK1044115A1 - Immunoadsorber for use in sepsis therapy - Google Patents

Immunoadsorber for use in sepsis therapy

Info

Publication number
HK1044115A1
HK1044115A1 HK02104556A HK02104556A HK1044115A1 HK 1044115 A1 HK1044115 A1 HK 1044115A1 HK 02104556 A HK02104556 A HK 02104556A HK 02104556 A HK02104556 A HK 02104556A HK 1044115 A1 HK1044115 A1 HK 1044115A1
Authority
HK
Hong Kong
Prior art keywords
immunoadsorber
sepsis
sepsis therapy
therapy
immunoadsorbers
Prior art date
Application number
HK02104556A
Other languages
English (en)
Inventor
Hans-Werner Heinrich
Hans-Jurgen Hahn
Udo Meyer
Peter Kruschke
Heinz-Jurgen Wagner
Original Assignee
Bioserv Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioserv Ag filed Critical Bioserv Ag
Publication of HK1044115A1 publication Critical patent/HK1044115A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK02104556A 1999-03-26 2002-06-19 Immunoadsorber for use in sepsis therapy HK1044115A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19913707A DE19913707A1 (de) 1999-03-26 1999-03-26 Immunadsorber zur Sepsistherapie
PCT/DE2000/000927 WO2000058005A2 (de) 1999-03-26 2000-03-23 Immunadsorber zur sepsistherapie

Publications (1)

Publication Number Publication Date
HK1044115A1 true HK1044115A1 (en) 2002-10-11

Family

ID=7902471

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104556A HK1044115A1 (en) 1999-03-26 2002-06-19 Immunoadsorber for use in sepsis therapy

Country Status (13)

Country Link
US (1) US6881408B1 (xx)
EP (1) EP1163004B1 (xx)
JP (1) JP4307743B2 (xx)
KR (1) KR100686364B1 (xx)
CN (1) CN1160126C (xx)
AT (1) ATE233571T1 (xx)
AU (1) AU760668B2 (xx)
CA (1) CA2366455C (xx)
DE (2) DE19913707A1 (xx)
ES (1) ES2193958T3 (xx)
HK (1) HK1044115A1 (xx)
IL (1) IL145557A (xx)
WO (1) WO2000058005A2 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
DE10118446A1 (de) * 2001-04-12 2002-10-17 Thomas Hartung Prüfverfahren zur Untersuchung fließfähiger Medien auf Gehalte an mikrobiellen Toxinen
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
EP1575507A2 (en) * 2002-04-02 2005-09-21 Scantibodies Laboratory, Inc. Methods and devices for treating severe peripheral bacterial infections
EP2266606B1 (en) * 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
EP1706079B1 (en) 2003-08-14 2013-02-20 ThromboGenics N.V. Antibodies against factor viii with modified glycosylation in the variable region
WO2005084198A2 (en) * 2004-02-27 2005-09-15 Vaxconsulting Peptides of il1 beta and tnf alpha and method of treatment using same
DE102004029573A1 (de) * 2004-06-18 2005-12-29 Gambro Lundia Ab MIF-Adsorbent
ITMI20041569A1 (it) * 2004-07-30 2004-10-30 Tecnogen Scpa "ligandi peptidici specifici per le immunoglobuline"
US20080255344A1 (en) * 2004-10-20 2008-10-16 Hans-Werner Heinrich Immuno-Adsorbers For Treatment of Inflammations
WO2007013945A2 (en) * 2005-07-20 2007-02-01 The Regents Of The University Of California Treating disorders associated with inflammation
WO2007024825A2 (en) * 2005-08-26 2007-03-01 Genway Biotech, Inc. Immunoaffinity separation and analysis compositions and methods
US8430831B2 (en) 2009-02-25 2013-04-30 The Invention Science Fund I, Llc Device, system, and method for controllably reducing inflammatory mediators in a subject
DE102009034150A1 (de) * 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
EP2679302A1 (de) 2012-06-28 2014-01-01 Zentrum für biomedizinische Technologie der Donau- Universität Krems Selektives Sorptionsmittel für die extrakorporale Blutreinigung
EP3185926B1 (de) 2014-08-26 2018-11-28 3M Innovative Properties Company System zur entfernung von proinflammatorischen mediatoren sowie von granulozyten und monozyten aus blut
EP3477300A1 (de) 2017-10-25 2019-05-01 Euroimmun Medizinische Labordiagnostika AG Zellulose-basierter immunadsorber
US20190247560A1 (en) * 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
WO2021063708A1 (en) 2019-09-30 2021-04-08 Hemotune Ag Assembly for extracorporeal treatment of body fluids
CN113967367A (zh) * 2020-07-25 2022-01-25 苏州仝乾医疗科技有限公司 新冠病毒治疗用细胞因子抗体组合物及治疗用吸附剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO162210C (no) * 1987-07-20 1989-11-22 Fasting Biotech As Monoklonale antistoffer mot c5a for in-vitro anvendelse ved immunologiske kvantitative teknikker eller ved isolering av c5a.
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US5626843A (en) * 1993-02-26 1997-05-06 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor
AU680897B2 (en) * 1993-03-16 1997-08-14 Aventis Pharmaceuticals Inc. Removal of selected factors from whole blood or its components and prevention and treatment of septic shock symdrome
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
DE19549420A1 (de) * 1995-04-27 1997-09-18 Braun Melsungen Ag Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma
US5922690A (en) 1996-04-25 1999-07-13 Van Gorp; Cornelius L. Dermatan disulfate, an inhibitor of thrombin generation and activation
US6287516B1 (en) * 1998-07-10 2001-09-11 Immunocept, L.L.C. Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease
US6193681B1 (en) * 1998-09-14 2001-02-27 American Immuno Tech, Llc. Septicemia prevention and treatment system

Also Published As

Publication number Publication date
EP1163004B1 (de) 2003-03-05
WO2000058005A3 (de) 2001-03-29
CN1160126C (zh) 2004-08-04
ATE233571T1 (de) 2003-03-15
DE19913707A1 (de) 2000-10-05
ES2193958T3 (es) 2003-11-16
KR100686364B1 (ko) 2007-02-23
JP4307743B2 (ja) 2009-08-05
IL145557A0 (en) 2002-06-30
KR20010112371A (ko) 2001-12-20
US6881408B1 (en) 2005-04-19
DE50001376D1 (de) 2003-04-10
CA2366455C (en) 2012-06-05
JP2002539910A (ja) 2002-11-26
WO2000058005A2 (de) 2000-10-05
AU760668B2 (en) 2003-05-22
CA2366455A1 (en) 2000-10-05
IL145557A (en) 2005-09-25
AU4742500A (en) 2000-10-16
CN1346280A (zh) 2002-04-24
EP1163004A2 (de) 2001-12-19

Similar Documents

Publication Publication Date Title
IL145557A0 (en) Immunoabsorber for use in sepsis therapy
IL145213A0 (en) Polyurethane solutions containing allkoxysilane structural units
TNSN06022A1 (en) Use of calcitonin in osteoarthritis
NO20013554L (no) Antikonvulsive derivater som kan benyttes ved behandling av klusterhodepiner
MXPA04001876A (es) Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis.
WO2001021766A8 (en) Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells
WO2004093817A3 (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
MXPA03000612A (es) Metodos y procesos mejorados para desinfeccion con yodo.
IL162005A0 (en) Copper deposition using copper formate complexes
DE60221155D1 (de) Negatif geladene polysaccharide aus aloe vera
AU7914600A (en) The use of baclofen in the treatment of alcohol withdrawal syndrome and to promote alcohol abstinence in alcoholics
MXJL05000046A (es) Mediadores de transporte reverso de colesterol para el tratamiento de hipercolesterolemia.
WO2001070253A8 (en) Use of mia in immunotherapy
MXPA01004291A (es) Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
MXPA05006734A (es) Nanoestructuras.
WO2004026895A3 (en) Gd2 ligands
GB2374871A (en) Peptide fragments of colostrinin and their use
IL139303A0 (en) Treatment of arthritis and other similar conditions
MD2053C2 (ro) Remediu cu acţiune interferonogenă
NZ514691A (en) Method to type prion proteins
MXPA05013595A (es) Proceso para aumentar la extraccion de liquido de las telas.
DE60138762D1 (de) Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren
UA32350A (uk) Спосіб лікування гострого інфаркту міокарда
WO2004037278A3 (de) Dyslokalisationsmoleküle und deren verwendung
UA32288A (uk) Спосіб лікування дегенеративних і запальних процесів

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150323